tb-500 vs bpc-157 Peptides for Recovery: TB500 vs Copper TB-500 Dosage Protocol: 3-Month Cycle

This represents a shift from "preclinical only" to early-stage clinical investigation

Populations who should not use BPC-157: Pregnant or breastfeeding individuals (no safety data), anyone with a history of cancer (theoretical concern given pro-angiogenic mechanisms), individuals taking anticoagulants (some animal data suggest effects on platelet aggregation pathways), and anyone without access to sterile technique for injection preparation

PDA shares the BPC-157 amino acid sequence and has no separate regulatory approval pathway

Other joints that are frequently affected include the mid-foot, ankle, knee, wrists and finger joints